NCT03065179View on ClinicalTrials.gov

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

February 20, 2020

Study Completion Date

November 17, 2020

Conditions
Kidney Cancer MetastaticKidney CancerKidney Cancer, Stage IV
Interventions
DRUG

Nivolumab/Ipilimumab

IV immunotherapy

RADIATION

SBRT

SBRT will be delivered in conjunction with immunotherapy

Trial Locations (2)

21287

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

75390

UT Southwestern, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03065179 - SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients | Biotech Hunter | Biotech Hunter